Inhibition of Breast Cancer Bone Metastasis by LRP5-Overexpressing Osteocytes via the LIMA1/MYO5B Signaling Axis
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27020777 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Yaning Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Pharmaceutical Sciences of Capital Medical University, Beijing 100069, China. Hauptthemen laut MEDLINE: Osteocytes, Bone Neoplasms, Low Density Lipoprotein Receptor-Related Protein-5, Breast Neoplasms. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, R&D Program of Beijing Municipal Education Commission.
Abstract (Originalsprache)
Bone metastasis in breast cancer remains a major therapeutic challenge because current osteoclast-targeted therapies do not fully disrupt the tumor–bone vicious cycle. Osteocytes, the most abundant bone cells, are increasingly recognized as key regulators of bone–tumor crosstalk. Previous work has shown that osteocyte-specific overexpression of the Wnt co-receptor LRP5 inhibits breast cancer-induced osteolysis and generates conditioned medium (CM) with tumor-suppressive activity. Proteomic analysis identified LIM domain and actin-binding protein 1 (LIMA1) as a central mediator that interacts with Myosin Vb (MYO5B), suggesting the role of the LIMA1/MYO5B regulatory axis. This study demonstrates that CM derived from LRP5-overexpressing osteocytes suppresses EO771 breast cancer cell proliferation, migration, and invasion, and downregulates tumor-promoting proteins, including MMP9, Snail, IL-6, and TGF-β1, while upregulating the apoptosis-related protein cleaved caspase-3. These effects were largely reversed by knockdown of LIMA1 or MYO5B. In syngeneic mouse models of mammary tumors and bone metastasis, systemic administration of LRP5-overexpressing osteocyte-derived CM reduced tumor burden and osteolytic bone destruction, whereas genetic knockdown of LIMA1 in osteocytes or MYO5B in tumor cells abrogated these protective effects. Collectively, these findings indicate that LRP5 activation in osteocytes engages the LIMA1/MYO5B signaling axis that inhibits breast cancer progression and osteolysis, disrupts tumor–stromal interactions, and restores bone–tumor homeostasis, thereby providing a potential therapeutic strategy to break the vicious cycle of bone metastasis in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, College of Pharmaceutical Sciences of Capital Medical University, Beijing 100069, China.
- Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Beijing 100069, C…
- Institute of Metallic Biomaterials, Helmholtz-Zentrum Hereon, 21502 Geesthacht, Germany.
- Department of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing 100069, China.
- Beijing Laboratory of Oral Health, Capital Medical University, Beijing 100069, China.
ORCID-Profile: Yu Sun
Förderung
- National Natural Science Foundation of China
- R&D Program of Beijing Municipal Education Commission
Zitieren
APA
Chen, Y., Wang, Z., Sun, Y., Li, X., Wang, Y., & Liu, S. (2026). Inhibition of Breast Cancer Bone Metastasis by LRP5-Overexpressing Osteocytes via the LIMA1/MYO5B Signaling Axis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020777
Vancouver
Chen Y, Wang Z, Sun Y, Li X, Wang Y, Liu S. Inhibition of Breast Cancer Bone Metastasis by LRP5-Overexpressing Osteocytes via the LIMA1/MYO5B Signaling Axis. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020777
BibTeX
@article{Chen2026,
author = {Chen, Yaning and Wang, Zicheng and Sun, Yu and Li, Xinshi and Wang, Yuji and Liu, Shengzhi},
title = {Inhibition of Breast Cancer Bone Metastasis by LRP5-Overexpressing Osteocytes via the LIMA1/MYO5B Signaling Axis},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27020777}
}
EUVIMED